Assistance Publique - Hopitaux De Paris (Aphp)

Institut National De La Sante Et De La Recherche Medicale

Université Paris Descartes

Université De Paris

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Assistance Publique-Hopitaux De Paris

Inserm

Bernard Mlecnik

Franck Pages

Jerome Galon

Herve Fridman

Gabriela Bindea

Jérôme Galon

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes

Growing community of inventors

Paris, France

Bernard Mlecnik